Skip to main content
Medigene AG logo

Medigene AG — Investor Relations & Filings

Ticker · MDG1 ISIN · DE000A40ESG2 LEI · 391200I33JD2DKZGDX06 F Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2018-04-04 Report Publication Anno…
Country DE Germany
Listing F MDG1

About Medigene AG

https://medigene.com/

Medigene AG is a biotechnology company that develops T-cell receptor (TCR)-guided immunotherapies for the treatment of cancer. The company utilizes its proprietary End-to-End platform to discover and develop optimized 3S (sensitive, specific, safe) TCRs. These TCRs are designed for application across various therapeutic modalities, including TCR-T cell therapies, TCR-T cell engagers, and TCR-natural killer cell therapies, targeting different forms of cancer. A key clinical program is MDG1015, a third-generation TCR-T therapy targeting the NY-ESO-1/LAGE-1a antigen, which is enhanced with a PD1-41BB costimulatory switch protein. As of August 2025, the company is undergoing insolvency proceedings.

Recent filings

Filing Released Lang Actions
Hinweis auf Jahresfinanzbericht vom 01.01.2017 bis zum 31.12.2017
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,100 characters) that explicitly states it is a 'Pre-announcement of a financial report' and provides a link to where the actual report can be found online. Following the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the report itself, making it a Report Publication Announcement (RPA).
2018-04-04 German
Datum:04.04.2018
Report Publication Announcement Classification · 100% confidence The document is a short announcement (approx. 1000 characters) titled 'Hinweis auf Halbjahresfinanzbericht' (Notice regarding the half-year financial report). It explicitly states that the company is announcing the publication of the report and provides a link to where it can be found online. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2018-04-04 German
Datum:09.08.2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for Medigene AG for the period ending June 30, 2017. It contains comprehensive financial statements, management discussion and analysis (Konzern-Zwischenlagebericht), and operational updates. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2017
2017-08-09 German
Datum:11.05.2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quartalsfinanzbericht' (Quarterly Financial Report) for Medigene AG for the period ending March 31, 2017. It contains detailed financial statements, including income statements, cash flow analysis, balance sheet data, and management commentary on business performance and outlook. It is not a short announcement or a certification, but a comprehensive interim report. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-11 German
Datum:25.04.2017
Interim / Quarterly Report Classification · 95% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Medigene AG for the fiscal year 2016. It includes the auditor's report ('Bestätigungsvermerk'), the management's declaration ('Versicherung der gesetzlichen Vertreter'), the balance sheet ('Bilanz'), the profit and loss statement ('Gewinn- und Verlustrechnung'), and the notes to the financial statements ('Anhang'). This constitutes a comprehensive annual financial report for a period shorter than a full fiscal year in terms of the reporting structure, but it is the primary annual financial disclosure. Given the definitions provided, this document represents the official annual financial reporting package, which aligns with the 'Interim / Quarterly Report' (IR) category for comprehensive financial reporting, or more accurately, the 'Annual Report' (10-K) category. Since it is a standalone annual financial statement (Jahresabschluss) rather than a full 10-K filing (which includes extensive business descriptions, risk factors, etc.), and given the specific categories, 'IR' is the most appropriate fit for a comprehensive financial report containing actual financial statements and analysis. FY 2016
2017-04-25 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2016 bis zum 31.12.2016
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Medigene AG for the fiscal year 2016. It contains detailed financial statements, key performance indicators (Kennzahlen), a management report (Konzern-Lagebericht), business strategy, and operational highlights. It is clearly a full annual report rather than a summary or announcement, as it provides extensive financial data and narrative analysis of the company's performance for the full fiscal year. FY 2016
2017-04-05 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.